FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462559027> ?p ?o ?g. }

• W2462559027 endingPage "6522" @default.
• W2462559027 startingPage "6522" @default.
• W2462559027 abstract "6522 Background: Green tea has long been touted as a health promoting substance. In vitro testing and a phase I trial suggest the green tea extract epigallocatechin 3 gallate(EGCG) may have clinical efficacy for chronic lymphocytic leukemia (CLL) patients. To follow-up on these results, we performed a phase II trial of daily EGCG in patients with CLL. Methods: Previously untreated patients with asymptomatic, Rai stage 0-II CLL and a minimum absolute lymphocyte count (ALC) ≥10 x109/L were eligible for participation. Polyphenon E with a standardized dose of EGCG (2,000 mg/dose) was administered twice daily for 6 months. Response was classified using the NCI Working Group (WG) Criteria. Results: Forty-two eligible patients received EGCG 2000 mg twice daily for up to 6 months. Patients received a median of 6 cycles of treatment (range: 1-6). Accrual to the trial is complete. Thirty-one patients have completed study therapy while 11 patients have not yet completed treatment. The most common side effects included transaminitis (31% grade 1, 12% grade 2), abdominal pain (21% grade 1, 7% grade 2, 2% grade 3), and nausea (55% grade 1, 2% grade 2). Only 2/48 (4.8%) patients experienced grade 3 toxicity. One patient experienced an NCI WG partial remission. Other signs of clinical activity were observed with 13 (31%) patients experiencing a sustained ≥ 20% reduction in ALC and 19 of 29 (66%) patients with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all nodal areas during treatment. Overall 28 (67%) patients fulfilled the criteria for a biologic response (JCO 27:3808) based on attaining either a sustained ≥ 20% decline in ALC and/or a ≥ 50% reduction in the sum of the products of all nodal areas at some point during the 6 months of active treatment. Conclusions: Daily oral EGCG in the Polyphenon E preparation was well tolerated by CLL patients in this phase II trial. Declines in ALC and/or lymphadenopathy were observed in the majority of patients. EGCG containing green tea extracts may have potential as disease stabilizing agents in patients with early-stage CLL. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, Genzyme, Novartis, Polyphenon E International FDA" @default.
• W2462559027 created "2016-07-22" @default.
• W2462559027 creator A5002515721 @default.
• W2462559027 creator A5022511085 @default.
• W2462559027 creator A5033825180 @default.
• W2462559027 creator A5034349428 @default.
• W2462559027 creator A5042585047 @default.
• W2462559027 creator A5044733637 @default.
• W2462559027 creator A5051752737 @default.
• W2462559027 creator A5059451077 @default.
• W2462559027 creator A5065087784 @default.
• W2462559027 creator A5087950597 @default.
• W2462559027 date "2010-05-20" @default.
• W2462559027 modified "2023-10-14" @default.
• W2462559027 title "Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL)." @default.
• W2462559027 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.6522" @default.
• W2462559027 hasPublicationYear "2010" @default.
• W2462559027 type Work @default.
• W2462559027 sameAs 2462559027 @default.
• W2462559027 citedByCount "5" @default.
• W2462559027 countsByYear W24625590272013 @default.
• W2462559027 countsByYear W24625590272022 @default.
• W2462559027 crossrefType "journal-article" @default.
• W2462559027 hasAuthorship W2462559027A5002515721 @default.
• W2462559027 hasAuthorship W2462559027A5022511085 @default.
• W2462559027 hasAuthorship W2462559027A5033825180 @default.
• W2462559027 hasAuthorship W2462559027A5034349428 @default.
• W2462559027 hasAuthorship W2462559027A5042585047 @default.
• W2462559027 hasAuthorship W2462559027A5044733637 @default.
• W2462559027 hasAuthorship W2462559027A5051752737 @default.
• W2462559027 hasAuthorship W2462559027A5059451077 @default.
• W2462559027 hasAuthorship W2462559027A5065087784 @default.
• W2462559027 hasAuthorship W2462559027A5087950597 @default.
• W2462559027 hasConcept C126322002 @default.
• W2462559027 hasConcept C141071460 @default.
• W2462559027 hasConcept C146357865 @default.
• W2462559027 hasConcept C151730666 @default.
• W2462559027 hasConcept C2777910003 @default.
• W2462559027 hasConcept C2777938653 @default.
• W2462559027 hasConcept C2778461978 @default.
• W2462559027 hasConcept C2780580376 @default.
• W2462559027 hasConcept C535046627 @default.
• W2462559027 hasConcept C71924100 @default.
• W2462559027 hasConcept C86803240 @default.
• W2462559027 hasConcept C90924648 @default.
• W2462559027 hasConceptScore W2462559027C126322002 @default.
• W2462559027 hasConceptScore W2462559027C141071460 @default.
• W2462559027 hasConceptScore W2462559027C146357865 @default.
• W2462559027 hasConceptScore W2462559027C151730666 @default.
• W2462559027 hasConceptScore W2462559027C2777910003 @default.
• W2462559027 hasConceptScore W2462559027C2777938653 @default.
• W2462559027 hasConceptScore W2462559027C2778461978 @default.
• W2462559027 hasConceptScore W2462559027C2780580376 @default.
• W2462559027 hasConceptScore W2462559027C535046627 @default.
• W2462559027 hasConceptScore W2462559027C71924100 @default.
• W2462559027 hasConceptScore W2462559027C86803240 @default.
• W2462559027 hasConceptScore W2462559027C90924648 @default.
• W2462559027 hasIssue "15_suppl" @default.
• W2462559027 hasLocation W24625590271 @default.
• W2462559027 hasOpenAccess W2462559027 @default.
• W2462559027 hasPrimaryLocation W24625590271 @default.
• W2462559027 hasRelatedWork W1987215768 @default.
• W2462559027 hasRelatedWork W1995188757 @default.
• W2462559027 hasRelatedWork W2016679923 @default.
• W2462559027 hasRelatedWork W2057721052 @default.
• W2462559027 hasRelatedWork W2116001782 @default.
• W2462559027 hasRelatedWork W2314711404 @default.
• W2462559027 hasRelatedWork W2423950151 @default.
• W2462559027 hasRelatedWork W2763646354 @default.
• W2462559027 hasRelatedWork W4229900919 @default.
• W2462559027 hasRelatedWork W4283155491 @default.
• W2462559027 hasVolume "28" @default.
• W2462559027 isParatext "false" @default.
• W2462559027 isRetracted "false" @default.
• W2462559027 magId "2462559027" @default.
• W2462559027 workType "article" @default.